Core Viewpoint - Boston Scientific Corporation has announced a definitive agreement to acquire Nalu Medical, Inc. to enhance its neuromodulation offerings for chronic pain management [1][2]. Acquisition Details - The acquisition involves an upfront cash payment of approximately $533 million for the remaining equity not owned by Boston Scientific, with a total transaction price of $600 million before adjustments [2][5]. - The transaction is expected to close in the first half of 2026, subject to customary closing conditions [4]. Product Information - The Nalu Neurostimulation System provides targeted relief for adults suffering from severe, intractable chronic pain through peripheral nerve stimulation (PNS) [2]. - The system features a miniaturized, battery-free implantable pulse generator, powered wirelessly and controlled via a smartphone app [2]. Clinical Efficacy - In clinical trials, the Nalu system demonstrated significant pain relief, with 87% of participants in the COMFORT trial reporting over 50% pain reduction at 12 months, and 79% in the COMFORT 2 trial achieving an average pain relief of 64% at six months [3]. - Real-world data from over 2,000 patients indicated that 94% experienced clinically meaningful improvement in chronic peripheral nerve pain conditions [3]. Financial Projections - Nalu Medical is projected to generate sales exceeding $60 million in 2025, with year-over-year growth anticipated to exceed 25% in 2026 [4]. - The acquisition is expected to be immaterial to adjusted earnings per share (EPS) in 2026, slightly accretive in 2027, and increasingly accretive thereafter [4].